A Phase II Study of M1774 in Refractory SPOP-mutant Prostate Cancer
Details
This phase II trial tests how well M1774 works in treating patients with prostate cancer that does not respond to treatment (refractory) and that has a mutation in the gene responsible for making the speckle type BTB/POZ protein (SPOP). M1774 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving M1774 may be able to shrink or stabilize refractory SPOP-mutant prostate cancer.
Eligibility
You can join if...
Inclusion Criteria:
Presence of SPOP mutations in prostate cancer cells, as indicated by Next Generation Sequencing (NGS)
Castrate-range testosterone (< 50 ng/dL) after androgen deprivation therapy (ADT) or orchiectomy
Prior treatment with second generation anti-androgen (2GAA) and taxane- or lutetium-based therapy
Exclusion Criteria:
Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia
Patients who are receiving any other investigational agents